Association of
            <i>TNF-</i>
            α Polymorphism with Prediction of Response to TNF Blockers in Spondyloarthritis and Inflammatory Bowel Disease: A Meta-Analysis

Tong, Qiang; Zhao, Liang; Qian, Xiao-Di; Zhang, Lanling; Xu, Xiufeng; Dai, Sheng‐Ming; Cai, Qing; Zhao, Dongbao

doi:10.2217/pgs.13.146

Cited by 33 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies found that the expression of TNF-α is higher in patients carrying the -308A allele than in those carrying the -308G allele, suggesting that this polymorphism has functional implications in inflammation and may be associated with inflammatory diseases [ 10 ]. In fact, previous studies have demonstrated the association of this polymorphism with certain inflammatory diseases, such as fatty liver disease [ 11 ], hepatitis B virus infection [ 12 ], systemic lupus erythematosus [ 13 ], inflammatory bowel disease [ 14 ], arteritis [ 15 ] and rheumatoid arthritis [ 16 ]. Several case–control studies have been conducted to clarify the association between the TNF-α -G308A polymorphism and risk of OA [ 17 – 23 ]; however, the results are inconsistent.…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of tumor necrosis factor alpha -308 polymorphism and knee osteoarthritis risk

Kou

2014

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundSeveral case–control studies have been conducted to clarify the association between the tumor necrosis factor alpha (TNF-α) -G308A polymorphism and risk of osteoarthritis (OA); however, the results are inconsistent. This meta-analysis was performed to clarify this issue using all the available evidence.MethodsEligible articles were retrieved by searching PubMed, Web of science and Google scholar. The strength of the association between the TNF-α -G308A polymorphism and risk of OA was assessed by odds ratios (ORs) with the corresponding 95% confidence interval (CI) for each study.ResultsSeven studies were included in the meta-analysis, which included 983 OA cases and 1355 controls. The pooled analysis based on all included studies showed a significantly increased OA risk in the recessive genetic model analysis (OR = 11.08, 95% CI = 4.75-25.86, p < 0.001) and in the A allele vs. G allele analysis (OR = 2.30, 95% CI = 1.08-4.90). However, there was no statistical difference in the dominant genetic model analysis (OR = 2.45, 95% CI = 0.95-6.27, p = 0.06). Furthermore, we found that OA patients had a higher frequency of the AA genotype (OR = 10.49, 95% CI = 4.47-24.61) and GA genotype (OR = 1.78, 95% CI = 1.03-3.08) compared with the control population.ConclusionOur results suggested that the TNF-α -G308A polymorphism were associated with an increased risk of OA.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2474-15-373) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Meta-analysis of tumor necrosis factor alpha -308 polymorphism and knee osteoarthritis risk

Kou

2014

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…In China, anti-TNF-α therapy is widely applied as treatment for various rheumatic diseases due to its clinical efficacy [ 15 – 16 ]. However, since their clinical availability in 2006, studies have reported adverse events inconsistent with original drug-safety profiles [ 17 ], and showed anti-TNF-α treatment can result in serious adverse events [ 18 – 19 ].…”

Section: Discussionmentioning

confidence: 99%

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis

et al. 2015

Self Cite

View full text Add to dashboard Cite

ObjectiveThis study aims to investigate the prevalence of short-term and long-term adverse events associated with tumor necrosis factor-α (TNF-α) blocker treatment in Chinese Han patients suffering from ankylosing spondylitis (AS).MethodsThe study included 402 Chinese Han AS patients treated with TNF-α blockers. Baseline data was collected. All patients were monitored for adverse events 2 hours following administration. Long-term treatment was evaluated at 8, 12, 52 and 104 weeks follow-up for 172 patients treated with TNF-α blockers.ResultsShort-term adverse events occurred in 20.15% (81/402), including rash (3.5%; 14/402), pruritus (1.2%; 5/402), nausea (2.2%; 9/402), headache (0.7%; 3/402), skin allergies (4.0%; 16/402), fever (0.5%; 2/402), palpitations (3.0%; 12/402), dyspnea (0.5%; 2/402), chest pain (0.2%; 2/402), abdominal pain (1.0%; 4/402), hypertension (2.2%; 9/402), papilledema (0.5%; 2/402), laryngeal edema (0.2%; 1/402) and premature ventricular contraction (0.2%; 1/402). Long-term adverse events occurred in 59 (34.3%; 59/172) patients, including pneumonia (7.6%; 13/172), urinary tract infections (9.9%; 17/172), otitis media (4.7%; 8/172), tuberculosis (3.5%; 17/172), abscess (1.2%; 2/172), oral candidiasis (0.6%; 1/172), elevation of transaminase (1.7%; 3/172), anemia (1.2%; 2/172), hematuresis (0.6%; 1/172), constipation (2.3%; 4/172), weight loss (0.6%; 1/172), exfoliative dermatitis (0.6%; 1/172). CRP, ESR and disease duration were found to be associated with an increased risk of immediate and long-term adverse events (P<0.05). Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc (P<0.01).ConclusionThis study reports on the prevalence of adverse events in short-term and long-term treatment with TNF-α blocker monotherapy in Chinese Han AS patients. Duration of disease, erythrocyte sedimentation rate, and c-reactive protein serum levels were found to be associated with increased adverse events with anti-TNF-α therapy. Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc.

show abstract

“…There are several important differences between the present study and two related meta-analyses that had been published previously3536. In the present study, we included more patients than either of the two previous studies and added a set of unpublished data from our lab.…”

Section: Discussionmentioning

confidence: 95%

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis

Liu

Zheng

Zhu

et al. 2016

Sci Rep

Self Cite

View full text Add to dashboard Cite

While previous studies have researched in association analyses between TNFα promoter polymorphisms and responses to TNF blockers in spondyloarthritis patients, their results were conflicting. Therefore, we aimed to determine whether TNFα promoter polymorphisms could predict response to TNF blockers and find the source of heterogeneity. Data were extracted and analyzed from published articles and combined with our unpublished data. We found that the greatest potential sources of heterogeneity in the results were gender ratio, disease type, continents, and TNF blockers. Then Stratification analysis showed that the TNFα −308 G allele and the −238 G allele predicted a good response to TNF blockers (OR = 2.64 [1.48–4.73]; 2.52 [1.46–4.37]). However, G alleles of TNFα −308 and −238 could predict the response to etanercept (OR = 4.02 [2.24–7.23]; 5.17 [2.29–11.67]) much more powerfully than the response to infiliximab/adalimumab (OR = 1.68 [1.02–2.78]; 1.28 [0.57–2.86]). TNFα −857 could not predict the response in either subgroup. Cumulative meta-analysis performed in ankylosing spondylitis patients presented the odds ratio decreased with stricter response criteria. In conclusion, TNFα −308 A/G and −238 A/G are more powerful to predict the response to Etanercept and it is dependent on the criteria of response.

show abstract

Association of TNF- α Polymorphism with Prediction of Response to TNF Blockers in Spondyloarthritis and Inflammatory Bowel Disease: A Meta-Analysis

Abstract: Individuals with the TNF-α-308 G allele and -857 C allele showed better anti-TNF-α treatment responses than those with the TNF-α-308 A allele and -857 T allele. The -308 G/G genotype and -857 C/C genotype are predictors of good response.

Cited by 33 publications

References 32 publications

Meta-analysis of tumor necrosis factor alpha -308 polymorphism and knee osteoarthritis risk

Meta-analysis of tumor necrosis factor alpha -308 polymorphism and knee osteoarthritis risk

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis

Contact Info

Product

Resources

About